MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
9.00
-0.03 (-0.33%)
Mar 31, 2025, 2:30 PM EDT - Market open

MiNK Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Selling, General & Admin
4.317.437.834.641.29
Upgrade
Research & Development
6.3415.4923.1213.979.51
Upgrade
Other Operating Expenses
0.64----
Upgrade
Operating Expenses
11.2922.9230.9518.6110.8
Upgrade
Operating Income
-11.29-22.92-30.95-18.61-10.8
Upgrade
Interest Expense
----2.43-2.44
Upgrade
Interest & Investment Income
0.170.460.25--
Upgrade
Currency Exchange Gain (Loss)
----0.410.49
Upgrade
Other Non Operating Income (Expenses)
0.15-0-0.090.630.35
Upgrade
EBT Excluding Unusual Items
-10.97-22.46-30.78-20.82-12.4
Upgrade
Gain (Loss) on Sale of Assets
0.19----
Upgrade
Other Unusual Items
--2.79-9.4-3.84
Upgrade
Pretax Income
-10.78-22.46-27.99-30.21-16.24
Upgrade
Net Income
-10.78-22.46-27.99-30.21-16.24
Upgrade
Net Income to Common
-10.78-22.46-27.99-30.21-16.24
Upgrade
Shares Outstanding (Basic)
43332
Upgrade
Shares Outstanding (Diluted)
43332
Upgrade
Shares Change (YoY)
9.82%2.04%29.38%7.95%0.21%
Upgrade
EPS (Basic)
-2.86-6.54-8.31-11.61-6.74
Upgrade
EPS (Diluted)
-2.86-6.54-8.31-11.61-6.74
Upgrade
Free Cash Flow
-9.56-15.84-19.12-13.08-8.43
Upgrade
Free Cash Flow Per Share
-2.53-4.61-5.68-5.02-3.50
Upgrade
EBITDA
-11.07-22.72-30.83-18.53-10.74
Upgrade
D&A For EBITDA
0.220.20.120.080.06
Upgrade
EBIT
-11.29-22.92-30.95-18.61-10.8
Upgrade
Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q